Inflammation in Intrahepatic Cholestasis of Pregnancy
Led by University Hospital, Brest · Updated on 2024-10-16
322
Participants Needed
11
Research Sites
N/A
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
This research aims to understand whether an immune process similar to allograft rejection causes intrahepatic cholestasis of pregnancy (ICP). The study includes pregnant women with and without ICP to explore if immunomodulatory treatments might be helpful. It is an observational study conducted by the University Hospital, Brest, focused on inflammation in ICP.
The study involves 322 pregnant women at delivery, divided into two groups: 161 women diagnosed with ICP and 161 without ICP. Blood tests will be performed on both mothers and newborns to measure various biological markers related to inflammation, allograft rejection, and angiogenesis. Placental tissue will also be analyzed to check for chronic inflammation.
Participants will provide blood samples and placenta at delivery for detailed analysis. Researchers will compare biological and placental markers between the ICP and non-ICP groups. The main outcome measured is the prevalence of placental chronic inflammation at delivery, alongside levels of biological factors involved in inflammation, rejection, and angiogenesis. The study will monitor these outcomes at delivery and conclude by June 2025.
CONDITIONS
Brief Title
Association of Intrahepatic Cholestasis of Pregnancy and Chronic Placental Inflammation
Who Can Participate
Age: 18Years - 60Years
FEMALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Adult pregnant woman with a single baby
For cases: diagnosed with intrahepatic cholestasis of pregnancy
For controls: no diagnosis of intrahepatic cholestasis of pregnancy
You will not qualify if you...
Younger than 18 years old
Under legal protection
Pregnant with twins or more
Delivery before 22 weeks of gestation
Medical termination of pregnancy
Acute chorioamnionitis, especially due to toxoplasmosis, rubella, CMV, or herpes virus
Premature rupture of membranes before 37 weeks of gestation
COVID-19 infection in the month before delivery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit at delivery (in-person)
Diagnostic Evaluation
Duration - At delivery
Participants undergo blood tests and placental analysis at delivery to measure biological parameters involved in inflammation, allograft rejection, and angiogenesis, and to assess chronic inflammation in the placenta.
1 visit at delivery (in-person)
Trial Site Locations
Total: 11 locations
1
CHU Angers
Angers, France
Not Yet Recruiting
2
Polyclinique KERAUDREN
Brest, France, 29200
Actively Recruiting
3
CHU de Brest
Brest, France, 29609
Actively Recruiting
4
CHU de Caen
Caen, France, 14000
Actively Recruiting
5
CH de Chambery
Chambéry, France, 75300
Actively Recruiting
6
CH Bretagne Sud
Lorient, France, 56100
Actively Recruiting
7
CHU Nantes
Nantes, France
Actively Recruiting
8
CH de Quimper
Quimper, France, 29000
Actively Recruiting
9
CHU de Rennes
Rennes, France, 35000
Actively Recruiting
10
CH St Brieuc
Saint-Brieuc, France
Actively Recruiting
11
CHU de Tours
Tours, France, 37044
Actively Recruiting
Loading map...
Research Team
C
Claire de Moreuil
P
Philippe Merviel
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Placental gene-expression profiles of intrahepatic cholestasis of pregnancy reveal involvement of multiple molecular pathways in blood vessel formation and inflammation.